| Abstract |
[Abstract] Objective: To explore the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression patients. Methods: The case data were collected and filed from March 2020 to March 2023. Totally 100 patients with depression were enrolled in the hospital. The participants were divided into control group (treated with venlafaxine hydrochloride sustained-release tablets) and observation group (control group, medication plan+rTMS treatment) based on the "random number table" 1:1 grouping, with 50 patients in each group; Observe and compare the levels of depression, cognitive function, serum thyroxine, and inflammatory cytokines between the two groups. Result: Compared with the control group, the observation group had significantly lower scores on the 17 items Hamilton Depression Scale (HAMD-17) after 2 and 4 weeks of treatment (P<0.05); After treatment, the scores of the Montreal Cognitive Function Assessment Scale (MoCA) and Minimal Mental State Examination (MMES) increased in both groups, and the observation group had a higher score (P<0.05); After treatment, two groups of tumor necrosis factor- α (TNF- α）、 Interleukin-6 (IL-6), Interleukin-1 β (IL-1 β） The levels all decreased, and the observation group was even lower (P<0.05); After treatment, the levels of triiodothyronine (T3), thyroid hormone (T4) and thyroid stimulating hormone (TSH) in both groups were higher than those before treatment in the same group, and higher than those in the control group (P<0.05). Conclusion: rTMS treatment can significantly improve the depressive state of patients with depression and insomnia, inhibit inflammatory factors, regulate serum thyroxine, and play a positive role in improving cognitive impairment.
|